Coherus Oncology, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dennis Lanfear
- Full Time Employees
- 144
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 333 Twin Dolphin Drive Redwood City CA United States of America 94065
- IPO Date
- Nov 6, 2014
- CIK
- 0001512762
- Website
- coherus.com
- Similar Companies
- Business
- Coherus Oncology, Inc. (Nasdaq: CHRS) develops and commercializes immuno-oncology therapies for cancer patients, with a focus on next-generation combination treatments targeting the tumor microenvironment; its approved products include LOQTORZI (toripalimab-tpzi), an anti-PD-1 monoclonal antibody indicated for recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy or as monotherapy; its pipeline features clinical-stage candidates such as casdozokitug, a first-in-class IL-27 antagonist evaluated in Phase 1/2 and Phase 2 trials for non-small cell lung cancer, hepatocellular carcinoma, and clear cell renal cell carcinoma; CHS-114, a cytolytic anti-CCR8 antibody in Phase 1 studies for advanced solid tumors including head and neck squamous cell carcinoma and gastric cancer; and CHS-1000, an anti-ILT4 antibody advancing toward first-in-human trials following FDA IND clearance in 2024. The company, founded in 2010 and headquartered in Redwood City, California, operates primarily in the United States with ongoing clinical trials across multiple solid tumor indications. In a strategic shift from biosimilars, Coherus completed the divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals in April 2025 for up to $558 million, following earlier sales of Cimerli and Humira biosimilars; it acquired Surface Oncology in September 2023, adding casdozokitug and CHS-114 to its portfolio; and continues to expand LOQTORZI through internal combinations with pipeline assets and planned external partnerships for label expansions in additional cancers.
Company News
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. Takes $16.80 Million Position in Coherus Oncology, Inc. $CHRS
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology Q2 Earnings Call Highlights
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology: Setting Up For Important Readouts In Mid-2026
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology Q1 Earnings Call Highlights
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update